CBMG - セルラ―・バイオメディシン・グル―プ (Cellular Biomedicine Group Inc.) セルラ―・バイオメディシン・グル―プ

 CBMGのチャート


 CBMGの企業情報

symbol CBMG
会社名 Cellular Biomedicine Group Inc (セルラ―・バイオメディシン・グル―プ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Cellular Biomedicine Group Inc. is engaged in the development of cell therapy technologies. The Company develops cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the goods manufacturing practices (GMP) laboratory. The Company's technology includes platforms such as Immune Cell therapy for treatment of broad range of cancers using Vaccine T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies Chimeric Antigen Receptor T cell (CAR-T) and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases with primary research and manufacturing facilities in China. The Company is focused on developing and marketing cell-based therapies based on its cellular platforms to treat serious chronic and degenerative diseases such as cancer orthopedic diseases.   セルラ―・バイオメディシン・グル―プは米国のバイオ医薬品企業。独自のセル技術を利用し、癌や変性疾患の新たな治療法の開発に従事。癌治療に腫瘍細胞特異的樹状細胞、関節疾患向けヒト脂肪由来間葉系前駆細胞、ヒト臍帯由来間葉系前駆細胞、中枢神経系疾患治療にヒト胚性運動ニュ―ロン前駆細胞およびヒト胚性神経前駆細胞を扱う。   
本社所在地 19925 Stevens Creek Blvd. Suite 100 Cupertino CA 95014 USA
代表者氏名 Terry A. Belmont テリー・A・ベルモント
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 408-973-7884
設立年月日 37043
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 125人
url www.cellbiomedgroup.com
nasdaq_url https://www.nasdaq.com/symbol/cbmg
adr_tso
EBITDA EBITDA(百万ドル) -28.33412
終値(lastsale) 17.52
時価総額(marketcap) 322722972.72
時価総額 時価総額(百万ドル) 255.27820
売上高 売上高(百万ドル) 0.30375
企業価値(EV) 企業価値(EV)(百万ドル) 220.49233
当期純利益 当期純利益(百万ドル) -46.80730
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cellular Biomedicine Group Inc revenues decreased 20% to $128K. Net loss increased 43% to $17.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other income decrease of 83% to $94K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.87 to -$1.03.

 CBMGのテクニカル分析


 CBMGのニュース

   Cerebral Palsy Market Global Key players- Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc. to 2023  2020/12/15 12:38:32 OpenPR
Market Scenario Cerebral palsy (CP) is a group of lifelong neurological disorders that affect movement and coordination, caused by damage to or abnormalities inside the developing brain of the infant. CP can occur before, during or soon after birth. Additionally, cerebral
   Cellular Biomedicine Group Announces Data to be Presented at 2020 ASH Annual Meeting  2020/12/04 12:35:00 PR Newswire
GAITHERSBURG, Md. and SHANGHAI, Dec. 4, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today…
   Cellular Biomedicine Group Reports Q3 2020 Financial Results and Business Highlights  2020/11/09 22:24:00 PR Newswire
GAITHERSBURG, Md. and SHANGHAI, Nov. 9, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported…
   Cellular Biomedicine Group Earnings and Growth Analysis : Stock market Insights & financial analysis  2020/11/04 19:47:00 Stock Market Daily
Cellular Biomedicine Group announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Cellular Biomedicine Group (NASDAQ:CBMG) Rating Increased to Hold at BidaskClub  2020/10/24 07:36:51 Zolmax News
Cellular Biomedicine Group (NASDAQ:CBMG) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Thursday, BidAskClub reports. Separately, Robert W. Baird downgraded shares of Cellular Biomedicine Group from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $28.00 […]
   Cerebral Palsy Market Global Key players- Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc. to 2023  2020/12/15 12:38:32 OpenPR
Market Scenario Cerebral palsy (CP) is a group of lifelong neurological disorders that affect movement and coordination, caused by damage to or abnormalities inside the developing brain of the infant. CP can occur before, during or soon after birth. Additionally, cerebral
   Cellular Biomedicine Group Announces Data to be Presented at 2020 ASH Annual Meeting  2020/12/04 12:35:00 PR Newswire
GAITHERSBURG, Md. and SHANGHAI, Dec. 4, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today…
   Cellular Biomedicine Group Reports Q3 2020 Financial Results and Business Highlights  2020/11/09 22:24:00 PR Newswire
GAITHERSBURG, Md. and SHANGHAI, Nov. 9, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported…
   Cellular Biomedicine Group Earnings and Growth Analysis : Stock market Insights & financial analysis  2020/11/04 19:47:00 Stock Market Daily
Cellular Biomedicine Group announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Cellular Biomedicine Group (NASDAQ:CBMG) Rating Increased to Hold at BidaskClub  2020/10/24 07:36:51 Zolmax News
Cellular Biomedicine Group (NASDAQ:CBMG) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Thursday, BidAskClub reports. Separately, Robert W. Baird downgraded shares of Cellular Biomedicine Group from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $28.00 […]
   SHAREHOLDER ALERT: WeissLaw LLP Investigates Cellular Biomedicine Group, Inc.  2020/08/13 00:38:00 Benzinga
NEW YORK , Aug. 12, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cellular Biomedicine Group, Inc. ("CBMG" or the "Company") (NASDAQ: CBMG ) in connection with the proposed interested-party … Full story available on Benzinga.com
   Cellular Biomedicine Group to take company private in merger agreement  2020/08/12 12:29:32 The Daily Record Maryland
Your subscription includes one set of login credentials for your exclusive use. Security features have been integrated on this site: If someone signs in with your credentials while you are logged in, the site will automatically close your ongoing login and you will lose access at that time.
   Cellular Biomedicine Group (CBMG) Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private  2020/08/12 10:30:00 PR Newswire
GAITHERSBURG, Md. and SHANGHAI, Aug. 12, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("Company," "CBMG," "we" or "our"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases,…
   Cellular Biomedicine Group (CBMG) Hosts R&D Showcase and Provides Updates to Clinical Programs  2020/07/13 11:29:00 PR Newswire
GAITHERSBURG, Md. and SHANGHAI, July 13, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, provided an…
   Cellular Biomedicine : CBMG to Host Investor R&D Showcase Highlighting Updates to Clinical Programs | MarketScreener  2020/07/01 14:24:14 MarketScreener
Cellular Biomedicine Group to Host Investor R&D Showcase Highlighting Updates to Clinical Programs GAITHERSBURG, MD and SHANGHAI,… | July 1, 2020

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セルラ―・バイオメディシン・グル―プ CBMG Cellular Biomedicine Group Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)